# CDR-Life

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cdr-life

- Industry: Biotechnology
- Headquarters: Zurich, Switzerland
- Website: www.cdr-life.com
- Total disclosed funding: $76M
- Latest round: Series A (Apr 13, 2022)
- Investors on record: 3

## About

Based in Zürich, Switzerland, and founded in 2017 by Christian Leisner (CEO), CDR-Life Inc. is a biotechnology company that develops antibody technology, to target cancer-specific intracellular proteins. In April 2022, CDR-Life Inc. raised USD 76 million in series A funding co-led by new investors Jeito Capital and RA Capital Management, with participation from another new investor Omega Funds. The company’s investors include RACAPITAL, Jeito, and Omega Funds.

The firm has developed the unique M-gager® technology to generate MHC-specific antibody-based T cell engagers that target highly tumor-specific intracellular antigens with unparalleled specificity. The company’s dual-MHC binding molecule format based on antibody fragments has the capability of developing new immunotherapies with high tumor cell killing potency, longer duration of effect, and lower risk of immune-related adverse effects. The company’s few programs include CDR404 which is the most advanced program of the company for solid tumors, CDR101 is a trispecific next-generation BCMA targeting therapy for the treatment of relapsed/refractory multiple myeloma (RRMM), and many others.

The company will use the April 2022 funding for the clinical trials of CDR404 and develop further its novel targeted immunotherapies based on CDR-Life’s superior T cell engaging platform.

## Funding rounds

- Series A, Apr 13, 2022, $76M — Omega Funds, RA Capital Management, Jeito Capital

## Investors

- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A
- Jeito Capital (https://capitalatlas.ai/funds/jeito-capital) — Series A